POSITION SUMMARY
Amunix is discovering highly potent cancer therapies that are optimized for minimal side effects using our universal, protease-releasable masking technology (Pro-XTEN). Our discovery process involves novel, highly-parallel assays that generate large sets of in vitro and in vivo data. We are currently seeking experienced computational scientists to join our discovery team. The candidates will report to the Head of Data Science and will be responsible for developing fit-for-purpose models to identify parameters that drive drug performance and to suggest strategies for improvement of drug performance. The candidates will also participate in quantitative systems pharmacology modeling efforts, statistical analyses (in support of both platform expansion and preclinical development), maintaining our preclinical database, and building analytical dashboards for analysis and interpretation of complex datasets. The successful candidate must be versatile and collaborative to thrive in a fast-paced, dynamic environment. This role in particular is a rare opportunity to join a passionate, highly-crossfunctional team that interfaces with discovery, bioanalytical, preclinical, and clinical teams during an exciting period of growth at Amunix. If you enjoy solving complicated puzzles and are interested in discovering medicines with the potential to drastically improve the lives of cancer patients, your application is highly welcome and encouraged.
ESSENTIAL FUNCTIONS
PREFERRED QUALIFICATIONS
ABOUT AMUNIX
Amunix is a Sanofi Center of Excellence that is leveraging our expertise in precision protein engineering to enable the promise of T cell engagers in solid tumors. Our goal is to improve the lives of people with cancer in pursuit of cures through the development and commercialization of breakthrough therapies that harness the immune system. We have designed XTEN, a validated therapeutic half-life extension technology. Our current focus is Pro-XTEN, a next-generation protease activated pro-drug platform, which enables selective activation of potent cancer therapies in the tumor microenvironment. This overcomes a common challenge facing potent immune system activators: on-target, off-tumor toxicity. Amunix’s lead programs employ the Pro-XTEN technology to enhance the safety profile of T cell engagers. XPATs (XTENylated Protease-Activated T Cell Engagers) have the potential to make off-the-shelf therapies redirecting T cells to solid tumors a reality.
Amunix provides equal employment opportunities (EEO) to all employees and applicants for employment without regard to race, color, religion, sex, national origin, age, disability, or genetics. In addition to federal law requirements, Amunix complies with applicable state and local laws governing nondiscrimination in employment in every location in which the company has facilities. This policy applies to all terms and conditions of employment, including recruiting, hiring, placement, promotion, termination, layoff, recall, transfers, leaves of absence, compensation, and training.
Please be advised that Amunix requires that all employees have the COVID-19 vaccination to work onsite unless the employee has an approved medical or religious exemption.
Safely Harnessing the Immune System to Conquer Cancer
0 jobsSubscribe to Rise newsletter